<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02795949</url>
  </required_header>
  <id_info>
    <org_study_id>SIMPLFY</org_study_id>
    <nct_id>NCT02795949</nct_id>
  </id_info>
  <brief_title>Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae</brief_title>
  <acronym>SIMPLIFY</acronym>
  <official_title>Randomized, Multicenter, Phase III, Controlled Clinical Trial, to Demonstrate the no Inferiority of Reduced Antibiotic Treatment vs a Broad Spectrum Betalactam Antipseudomonal Treatment in Patients With Bacteremia by Enterobacteriaceae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Network for Research in Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The continuous increase in the bacterial resistance rate and the slow arrival of new
      therapeutic options have turned into an antibiotic crisis. One of the strategies proposed by
      stewardship programs to try to change this situation described worldwide is the use of
      antibiotics with the lowest possible antimicrobial spectrum.

      Enterobacteriaceae bacteremia is a good example of how this strategy would be applied. The
      empirical treatment of nosocomial bacteremia by Enterobacteriaceae comprises in several cases
      one or two antibiotics with antipseudomonal activity, being much less common than desirable a
      subsequent change to narrower spectrum antibiotics based on susceptibility data (&quot;de
      escalation&quot;). This is because the safety of de escalation is based only on expert advice and
      some observational studies, so their efficacy and safety is questioned by many clinicians and
      therefore its use is lower than desired. In fact, a recent systematic review of the Cochrane
      Library concluded that randomized studies to support this practice are needed. Investigators
      propose a &quot;real clinical practice-based&quot; randomized trial to compare the efficacy and safety
      of continuing with an antipseudomonal agents vs. de-escalation according to a pre-specified
      rule, in patients with bacteraemia due to Enterobacteriaceae.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure at day 3-5 after treatment.</measure>
    <time_frame>Day 3-5 after end of treatment.</time_frame>
    <description>Clinical cure: complete resolution of infection symptoms (bacteremia) present at the day on which the assessment is done and patient is alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early clinical and microbiological response.</measure>
    <time_frame>After 5 days of treatment</time_frame>
    <description>The infection was completely resolved after 5 days of treatment (patients without infection symptoms and a negative blood culture).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late clinical and microbiological response.</measure>
    <time_frame>Day 60</time_frame>
    <description>The infection was completely resolved at day 60 (patients without infection symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>At 7,14 and 30 days</time_frame>
    <description>Death for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>At 7,14 and 30 days</time_frame>
    <description>Defined as the from admission to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrences (relapse or reinfection) rate</measure>
    <time_frame>Day 60 after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of antibiotic treatment</measure>
    <time_frame>60 days</time_frame>
    <description>Gathering any related adverse event from the informed consent form signature up to 60 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the study treatment on intestinal microbiota</measure>
    <time_frame>Screening, Day 7-14, Day 12-21, Day 30</time_frame>
    <description>Effect of study treatment on colonization of the intestinal tract with multi drug resistant gram negative bacilli</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment duration.</measure>
    <time_frame>It is not allowed treatment duration more than 28 days</time_frame>
    <description>Evaluate the study treatment duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary infections.</measure>
    <time_frame>60 days</time_frame>
    <description>Evaluate the development of secondary infections other than the initial bacteremia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">344</enrollment>
  <condition>Enterobacteriaceae Infections</condition>
  <arm_group>
    <arm_group_label>Antipseudomonal beta-lactam antibiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ampicillin 2g IV/6h
Trimethoprim/sulfamethoxazole 160/800 mg IV/8 -12h
Cefuroxime 750-1000 mg IV/8h
Cefotaxime 1-2g IV/8h ó ceftriaxone 1 g/12-24h
Amoxicillin/clavulanate 1000/125 mg IV/8h
Ciprofloxacin 400 mg IV/12h
Ertapenem 1-2g/24h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>De-escalation(short-spectrum antibiotic)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Piperacillin/tazobactam 4/0.5 g IV/8h
Meropenem 1-2 g IV/8h
Imipenem 0.5 g IV/6h - 1g IV/6h
Aztreonam 1-2 g IV/8h
Ceftazidime 1-2 g IV/8h
Cefepime 2 g IV/8-12h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antipseudomonal beta-lactam antibiotic</intervention_name>
    <description>Pharmaceutical form: solution for infusion</description>
    <arm_group_label>Antipseudomonal beta-lactam antibiotic</arm_group_label>
    <other_name>Ampicillin</other_name>
    <other_name>Trimethoprim/sulfamethoxazole</other_name>
    <other_name>Cefuroxime</other_name>
    <other_name>Amoxicillin/clavulanate</other_name>
    <other_name>Ciprofloxacin</other_name>
    <other_name>Ertapenem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>De-escalation(short-spectrum antibiotic)</intervention_name>
    <description>Pharmaceutical form: solution for infusion</description>
    <arm_group_label>De-escalation(short-spectrum antibiotic)</arm_group_label>
    <other_name>Piperacillin/tazobactam</other_name>
    <other_name>Meropenem</other_name>
    <other_name>Imipenem</other_name>
    <other_name>Aztreonam</other_name>
    <other_name>Ceftazidime</other_name>
    <other_name>Cefepime</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥18 years old hospitalized patients with bacteremia from any source with isolation of
             an enterobacteria in blood cultures.

          2. Active empiric treatment with antipseudomonal betalactamic at 48 hours from the
             symptoms of sepsis and the blood culture.The patient could have received any other
             type of antibiotic therapy up to 24 hours after blood extraction.

          3. Microorganism susceptible at least one treatment from the experimental arm.

          4. Patients with intravenous treatment at least 3 days from the randomization o 5 days
             from the initial blood culture.

          5. Patients to sign the informed consent form.

        Exclusion Criteria:

          1. Palliative care or life expectance &lt; 90 days.

          2. Pregnancy or lactation period.

          3. To isolate the Extended-spectrum β-lactamases producing Enterobacteriaceae

          4. Late randomization &gt;48 hours after the enterobacteriaceae blood culture´s
             identification

          5. Severe neutropenic (&lt; 500 céls/mm3) at the randomization.

          6. Treatment of infection &gt; 28 days (endocarditis and osteomyelitis) or meningitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Eduardo Lopez Cortes, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitary Hospital Virgen Macarena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clara Rosso Fernández, MD, PhD</last_name>
    <phone>0034 955016414</phone>
    <email>claram.rosso.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eva Recio, BS, PhD</last_name>
    <phone>600162652</phone>
    <email>eva.recio.exts@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jerez de la Frontera Hospital</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <zip>11138</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvador Pérez Cortes, MD</last_name>
      <email>salvador.perez.cortes.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Línea de La Concepción Hospital</name>
      <address>
        <city>La Línea de La Concepción</city>
        <state>Cádiz</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Donostia</name>
      <address>
        <city>San Sebastian</city>
        <state>Gipúzcoa</state>
        <zip>20080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maialen Ibarguren Pinilla, MD</last_name>
      <email>MAIALEN.IBARGURENPINILLA@osakidetza.eus</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cruces Hospital</name>
      <address>
        <city>Baracaldo</city>
        <state>País Vasco</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josune Goikoetxea Agirre</last_name>
      <email>ANEJOSUNE.GOIKOETXEAAGIRRE@osakidetza.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Juan de Dios del Aljarafe Hospital</name>
      <address>
        <city>Bormujos</city>
        <state>Sevilla</state>
        <zip>41930</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esperanza Merino de Lucas, MD</last_name>
      <email>merino_luc@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Mutua de Tarrasa</name>
      <address>
        <city>Barcelona</city>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucía Gómez García, MD</last_name>
      <email>lgomez@mutuaterrassa.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Cuervo Requena</last_name>
      <email>guillermocuervo@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Puerta del Mar</name>
      <address>
        <city>Cádiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisca Guerrero Sánchez, MD, PhD</last_name>
      <email>fcam.gs@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Puerto Real Hospital</name>
      <address>
        <city>Cádiz</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Jimenez, MD</last_name>
      <email>patriciajaguilar@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Coruña Hospital</name>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>German Bou Arévalo</last_name>
      <email>germanbou@canalejo.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitary Hospital of Leon</name>
      <address>
        <city>León</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Manuel Guerra Laso</last_name>
      <email>jmglaso@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Salas Aparicio, MD</last_name>
      <email>asalasapa@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belen Loeches Yagüe, MD, Ms.C</last_name>
      <email>bloeches@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitary Hospital of Orense</name>
      <address>
        <city>Orense</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MªDolores Díaz Lòpez</last_name>
      <email>Maria.Dolores.Diaz.Lopez@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Son Espases Hospital</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª Luisa Martín Pena, MD</last_name>
      <email>lmartinpena@ssib.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic of Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Ramón Yuste Ara, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª Carmen Fariñas Álvarez, MD, PhD</last_name>
      <email>mcfarinas@humv.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen Macarena</name>
      <address>
        <city>Seville</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Eduardo López Cortés, MD, PhD</last_name>
      <email>luiselopezcortes@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitary Hospital of Vigo</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MªTeresa Pérez Rodriguez</last_name>
      <email>maria.teresa.perez.rodriguez2@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Ramón Paño Pardo, MD, PhD</last_name>
      <email>joserrapa@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.reipi.org/</url>
    <description>Spanish Network for Research in Infectious Diseases (Red Española de Investigación en Patología Infecciosa)</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Enterobacteriaceae</keyword>
  <keyword>Bacteremia</keyword>
  <keyword>Escalation</keyword>
  <keyword>Bacterial resistance</keyword>
  <keyword>Bloodstream infection</keyword>
  <keyword>Recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Enterobacteriaceae Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Ertapenem</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Ampicillin</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Cefuroxime</mesh_term>
    <mesh_term>Aztreonam</mesh_term>
    <mesh_term>Lactams</mesh_term>
    <mesh_term>Cefepime</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>beta-Lactams</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

